UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
January 30, 2007
Commission File Number: 0-52039
Tm Bioscience Corporation
(Exact name of registrant as specified in its charter)
439 University Avenue, Suite 2000, Toronto, Ontario, Canada M5G 1Y8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1). _________
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7). _________
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below if the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82-_____
EXHIBIT NUMBER | | DESCRIPTION |
| | |
99.1 | | Press release, dated January 30, 2007, Tm Bioscience to Supply Tag-It™ Reagents for Personalized Medicine Study |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 30, 2007
TM BIOSCIENCE CORPORATION |
(Registrant) |
| | |
By: | /s/ James Pelot |
Name: | | James Pelot |
Title: | | Chief Financial Officer and Chief Operating Officer |